+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

India Oncology NGS Market Size, Share & Trends Analysis Report by End-use (Clinical Research, Hospitals & Clinics), Technology, Application, Product & Service, Workflow, and Segment Forecasts, 2021-2028

  • ID: 5513914
  • Report
  • December 2021
  • Region: India
  • 158 Pages
  • Grand View Research

FEATURED COMPANIES

  • 4BASECARE
  • ILLUMINA, INC.
  • MYRIAD GENETICS, INC.
  • PERKIN ELMER, INC.
  • SAYRE THERAPEUTICS
  • TECAN TRADING AG
The India oncology NGS market is expected to reach USD 70.60 million by 2028, registering a CAGR of 19.6% over the forecast period, according to the report. The development of companion diagnostic assays for personalized medicine, growing adoption of sequencing platforms for cancer diagnosis, and increasing investment for the development of genomic databases are the key driving factors for market growth.





The increasing need for user-friendly sequencing workflows along with cost-effective solutions contribute to the rising adoption rate of this technology in India. The availability of the genome database for the Indian population eases the process of developing companion diagnostics & personalized medicine and offers access to stratified samples for the research. In addition, a rise in cancer incidence in India is expected to be a high impact rendering driver of the market. For instance, the WHO states that 851,678 deaths and over 1,324,413 cancer cases were registered in 2020 in India.

The COVID-19 pandemic had a cascading effect on the supply chain of next-generation sequencing and delayed various sequencing projects. For instance, Illumina experienced a shortfall in the supply of reagents’ raw materials and caused delays in reagents delivery by weeks, which is usually in days. Similarly, various Next Generation Sequencing (NGS)resources were pulled out from oncology development to the COVID-19 study.

Next-generation sequencing technology was able to screen multiple samples and identify the virus without prior inputs of the infection. It was further used for surveillance and epidemiological studies. Although oncology NGS was not a very active segment in COVID-19, the overall demand for NGS products will affect the price level in the market.

India Oncology NGS Market Report Highlights

  • The targeted & gene panel sequencing segment held the major market share in 2020 as targeted panels offer economical solutions for providing actionable and clear information to the physicians
  • The research studies segment occupied a major share of the applications in 2020 owing to the increasing usage of NGS technology for oncology research in India
  • The diagnostics and screening segment is anticipated to grow at the fastest CAGR from 2021 to 2028 owing to increasing recommendations for oncology screening and the high adoption rate of NGS-based molecular diagnosis of cancer
  • The platforms and related products segment are expected to account for the maximum revenue share by 2028. Ongoing research to evaluate the performance of various targeted NGS gene panels regarding their technical features and clinical utility is driving the adoption rate in this segment
  • The sequencing segment led the market in 2020 and is estimated to expand further at the fastest growth rate from 2021 to 2028 as it is the most critical phase in the workflow
  • The clinical research segment is expected to grow at the fastest CAGR from 2021 to 2028 owing to the use of NGS in cancer research and, more specifically, in the discovery of new cancer-related genes, studying tumor heterogeneity, and identification of alterations that contribute to tumorigenesis
  • The Indian market is marked by the presence of distributors of global leaders. For instance, Premas Life Sciences Pvt. Ltd. is a registered distributor of Illumina in India. Premas Life Sciences Pvt. Ltd. and Medgenome Labs are two of the largest players in the Indian market


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Indian Oncology NGS Market

What is the estimated value of the Indian Oncology NGS Market?

The Indian Oncology NGS Market was estimated to be valued at $19.7 Million in 2021.

What is the growth rate of the Indian Oncology NGS Market?

The growth rate of the Indian Oncology NGS Market is 19.6%, with an estimated value of $70.6 Million by 2028.

What is the forecasted size of the Indian Oncology NGS Market?

The Indian Oncology NGS Market is estimated to be worth $70.6 Million by 2028.

Who are the key companies in the Indian Oncology NGS Market?

Key companies in the Indian Oncology NGS Market include ILLUMINA, INC., GENOTYPIC TECHNOLOGY PVT. LTD., TECAN TRADING AG, SCIGENOM LABS PVT. LTD, XCELRIS LABS LTD. (XCELRIS GENOMICS), EUROFINS SCIENTIFIC, 4BASECARE, MEDGENOME and REDCLIFFE LIFE SCIENCES PVT. LTD..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 4BASECARE
  • ILLUMINA, INC.
  • MYRIAD GENETICS, INC.
  • PERKIN ELMER, INC.
  • SAYRE THERAPEUTICS
  • TECAN TRADING AG

Chapter 1 Methodology and Scope
1.1 Research Assumptions
1.2 Research Methodology
1.3 Information Procurement
1.4 Information or Data Analysis
1.5 Market Formulation & Validation
1.6 Model
1.7 Market Model
1.8 Global Market: CAGR Calculation
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Landscape
2.4 Market Summary
Chapter 3 India Oncology Next Generation Sequencing Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping, by Technology, 2020
3.3 Next-Generation Sequencing Reimbursement Environment
3.3.1 Role Of The Commercial Payers
3.4 Regulatory and Political Environment
3.5 Market Dynamics
3.5.1 Market Driver Analysis
3.5.1.1 Exponentially decreasing costs for genetic sequencing
3.5.1.2 Development of companion diagnostics and personalized medicine
3.5.1.3 Technological advancements in cloud computing and data integration
3.5.1.4 Increasing prevalence of cancer
3.5.2 Market Restraint Analysis
3.5.2.1 Lack of computational efficiency for data management
3.5.2.2 Challenges associated with NGS implementation
3.5.3 Market Opportunity Analysis
3.5.3.1 Efforts taken to develop genomic databases for the Indian population
3.6 Business Environment Analysis
3.6.1 Swot Analysis; By Factor (Political & Legal, Economic and Technological)
3.6.2 Porter’s Five Forces Analysis
3.7 Impact of COVID-19 Pandemic
3.7.1 Impact On The Supply Chain
3.7.2 Role Of Ngs To Combat COVID-19 Outbreak
3.7.3 Key Initiatives In India
Chapter 4 India Oncology Next Generation Sequencing Market: Competitive Analysis
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.2 Company/Competition Categorization
4.3 Major Deals & Strategic Alliances Analysis
4.3.1 Mergers & Acquisitions
4.3.2 Licensing, Partnership Joint Ventures, & Collaborations
4.4 Market Entry Strategies
Chapter 5 Technology Business Analysis
5.1 India Oncology NGS Market: Technology Movement Analysis
5.2 Whole Genome Sequencing
5.2.1 India Oncology Whole Genome Sequencing Market Estimates and Forecast, 2017 - 2028 (USD Million)
5.2.2 Whole Exome Sequencing
5.2.2.1 India Oncology Whole Exome Sequencing Market Estimates and Forecast, 2017 - 2028 (USD Million)
5.2.3 Targeted & Gene Panel Sequencing
5.2.3.1 India Oncology Targeted & Gene Panel Sequencing Market Estimates and Forecast, 2017 - 2028 (USD Million)
5.2.4 Amplicon-Based
5.2.4.1 India oncology NGS Amplicon-based market estimates and forecast, 2017 - 2028 (USD Million)
5.2.5 Hybridization-Based
5.2.5.1 India oncology NGS Hybridization-based market estimates and forecast, 2017 - 2028 (USD Million)
Chapter 6 Application Business Analysis
6.1 India Oncology NGS Market: Application Movement Analysis
6.2 Diagnostics and Screening
6.2.1 India Ngs-Based Oncology Diagnostics and Screening Market Estimates and Forecast, 2017 - 2028 (USD Million)
6.2.2 Screening
6.2.2.1 India NGS-based oncology screening market estimates and forecast, 2017 - 2028 (USD Million)
6.2.2.2 Sporadic Cancer Screening
6.2.2.2.1 India NGS-based sporadic cancer screening market estimates and forecast, 2017 - 2028 (USD Million)
6.2.2.3 Inherited Cancer Screening
6.2.2.3.1 India NGS-based inherited cancer screening market estimates and forecast, 2017 - 2028 (USD Million)
6.2.3 Companion Diagnostics (CDX)
6.2.3.1 India NGS-based oncology CDx market estimates and forecast, 2017 - 2028 (USD Million)
6.2.4 Other Diagnostics
6.2.4.1 India NGS-based oncology CDx market estimates and forecast, 2017 - 2028 (USD Million)
6.3 Research Studies
6.3.1 India Ngs-Based Oncology Research Studies Market Estimates and Forecast, 2017 - 2028 (USD Million)
Chapter 7 Product & Service Business Analysis
7.1 India Oncology Next-Generation Sequencing Market: Product & Service Movement Analysis
7.2 NGS Platforms and Related Products
7.2.1 India Oncology Ngs Platforms and Related Products Market Estimates and Forecast, 2017 - 2028 (USD Million)
7.2.2 Panel
7.2.2.1 India oncology NGS panel market estimates and forecast, 2017 - 2028 (USD Million)
7.2.3 Consumables
7.2.3.1 India oncology NGS consumables market estimates and forecast, 2017 - 2028 (USD Million)
7.2.4 Platforms
7.2.4.1 India oncology NGS platforms market estimates and forecast, 2017 - 2028 (USD Million)
7.3 NGS Services
7.3.1 India Oncology Ngs Services Market Estimates and Forecast, 2017 - 2028 (USD Million)
Chapter 8 Workflow Business Analysis
8.1 India Oncology NGS Market: Workflow Movement Analysis
8.2 Pre-Sequencing
8.2.1 India Oncology Ngs Pre-Sequencing Market Estimates and Forecast, 2017 - 2028 (USD Million)
8.2.2 Ngs Library Preparation Kits
8.2.2.1 India oncology NGS Library Preparation kits market estimates and forecast, 2017 - 2028 (USD Million)
8.2.3 Semi-Automated Library Preparation
8.2.3.1 India oncology Semi-Automated Library Preparation market estimates and forecast, 2017 - 2028 (USD Million)
8.2.4 Automated Library Preparation
8.2.4.1 India oncology automated Library Preparation market estimates and forecast, 2017 - 2028 (USD Million)
8.2.5 Clonal Amplification
8.2.5.1 India oncology clonal amplification market estimates and forecast, 2017 - 2028 (USD Million)
8.3 Sequencing
8.3.1 India Oncology Ngs Sequencing Market Estimates and Forecast, 2017 - 2028 (USD Million)
8.4 NGS Data Analysis
8.4.1 India Oncology Ngs Data Analysis Market Estimates and Forecast, 2017 - 2028 (USD Million)
8.4.2 Ngs Primary Data Analysis
8.4.2.1 India oncology NGS primary data analysis market estimates and forecast, 2017 - 2028 (USD Million)
8.4.3 Ngs Secondary Data Analysis
8.4.3.1 India oncology NGS secondary data analysis market estimates and forecast, 2017 - 2028 (USD Million)
8.4.4 Ngs Tertiary Data Analysis
8.4.4.1 India oncology NGS tertiary data analysis market estimates and forecast, 2017 - 2028 (USD Million)
Chapter 9 End-Use Business Analysis
9.1 India Oncology Next Generation Sequencing Market: End-use Movement Analysis
9.2 Academic Research
9.2.1 Academic Research-Based India Oncology Ngs Market Estimates and Forecast, 2017 - 2028 (USD Million)
9.3 Clinical Research
9.3.1 Clinical Research-Based India Oncology Ngs Market Estimates and Forecast, 2017 - 2028 (USD Million)
9.4 Hospitals & Clinics
9.4.1 Hospitals & Clinics -Based India Oncology Ngs Market Estimates and Forecast, 2017 - 2028 (USD Million)
9.5 Pharma & Biotech Entities
9.5.1 Pharma & Biotech Entities-Based India Oncology Ngs Market Estimates and Forecast, 2017 - 2028 (USD Million)
9.6 Other Users
9.6.1 Other Users-Based India Oncology Ngs Market Estimates and Forecast, 2017 - 2028 (USD Million)
Chapter 10 Competitive Landscape
10.1 Company Profiles
10.1.1 ILLUMINA, INC.
10.1.1.1 Company Overview
10.1.1.2 Financial Performance
10.1.1.3 Product Benchmarking
10.1.1.4 Strategic Initiatives
10.1.2 GENOTYPIC TECHNOLOGY PVT. LTD.
10.1.2.1 Company Overview
10.1.2.2 Product Benchmarking
10.1.3 TECAN TRADING AG
10.1.3.1 Company Overview
10.1.3.2 Financial Performance
10.1.3.3 Product Benchmarking
10.1.3.4 Strategic Initiatives
10.1.4 SCIGENOM LABS PVT. LTD
10.1.4.1 Company Overview
10.1.4.2 Product Benchmarking
10.1.4.3 Strategic Initiatives
10.1.5 XCELRIS LABS LTD. (XCELRIS GENOMICS)
10.1.5.1 Company Overview
10.1.5.2 Product Benchmarking
10.1.6 EUROFINS SCIENTIFIC
10.1.6.1 Company Overview
10.1.6.2 Financial Performance
10.1.6.3 Product Benchmarking
10.1.6.4 Strategic Initiatives
10.1.7 4BASECARE
10.1.7.1 Company Overview
10.1.7.2 Financial Performance
10.1.7.3 Product Benchmarking
10.1.7.4 Strategic Initiatives
10.1.8 MEDGENOME
10.1.8.1 Company Overview
10.1.8.2 Product Benchmarking
10.1.8.3 Strategic Initiatives
10.1.9 SAYRE THERAPEUTICS
10.1.9.1 Company Overview
10.1.9.2 Product Benchmarking
10.1.9.3 Strategic Initiatives
10.1.10 REDCLIFFE LIFE SCIENCES PVT. LTD.
10.1.10.1 Company Overview
10.1.10.2 Product Benchmarking
10.1.11 PARTEK INCORPORATED
10.1.11.1 Company Overview
10.1.11.2 Financial Performance
10.1.11.3 Product Benchmarking
10.1.11.4 Strategic Initiatives
10.1.12 BIO-RAD LABORATORIES, INC.
10.1.12.1 Company Overview
10.1.12.2 Financial Performance
10.1.12.3 Product Benchmarking
10.1.12.4 Strategic Initiatives
10.1.13 MYRIAD GENETICS, INC.
10.1.13.1 Company Overview
10.1.13.2 Financial Performance
10.1.13.3 Product Benchmarking
10.1.13.4 Strategic Initiatives
10.1.14 HOLOGIC, INC. (GEN-PROBE INCORPORATED)
10.1.14.1 Company Overview
10.1.14.2 Financial Performance
10.1.14.3 Product Benchmarking
10.1.14.4 Strategic Initiatives
10.1.15 PERKIN ELMER, INC.
10.1.15.1 Company Overview
10.1.15.2 Horizon Discovery Group plc
10.1.15.2.1 Company Overview
10.1.15.3 Financial Performance
10.1.15.4 Product Benchmarking
10.1.15.5 Strategic Initiatives
10.1.16 VELA DIAGNOSTICS
10.1.16.1 Company Overview
10.1.16.2 Financial Performance
10.1.16.3 Product Benchmarking
10.1.16.4 Strategic Initiatives
10.1.17 PREMAS LIFE SCIENCES
10.1.17.1 Company Overview
10.1.17.2 Financial Performance
10.1.17.3 Product Benchmarking
List of Tables
Table 1 Top 5 cancer insurance plans in India
Table 2 Quantitative outcome of government initiatives for genomics in India (2015 - 2020)
Table 3 NGS DNA testing cost in India
Table 4 Illumina Workflows to Address COVID-19
Table 5 Genes covered in Redcliffe Life sciences’ comprehensive hereditary cancer panel
Table 6 Library preparation kits used by MedGenome
Table 7 NGS platform users
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 QFD modeling for market share assessment of NGS data analysis workflows
Fig. 9 Commodity flow analysis
Fig. 10 Market segmentation & scope
Fig. 11 India oncology NGS market snapshot, USD Million, 2020
Fig. 12 Generations of sequencing
Fig. 13 Different NGS technologies and types of analysis
Fig. 14 Common DNA sequencing methods
Fig. 15 Penetration and growth prospect mapping, by technology
Fig. 16 Medical vs. non-medical expenditure for cancer care in India
Fig. 17 Key priority areas of Human Genetics & Genome Analysis program of DBT
Fig. 18 Key initiatives of DBT India
Fig. 19 India oncology NGS market driver impact
Fig. 20 Estimated number of new cancer cases in India, both sexes, age: 0-85+ (Million cases)
Fig. 21 India oncology NGS market restraint impact
Fig. 22 India oncology NGS market opportunity impact
Fig. 23 SWOT analysis, by factor (Political & legal, economic, and technological)
Fig. 24 Porter’s Five Forces Analysis
Fig. 25 Key macroeconomic challenges associated with the pandemic
Fig. 26 Key elements to enhance the supply chain post COVID-19
Fig. 27 Role of NGS to combat COVID-19 outbreak
Fig. 28 Recent developments & impact analysis, by key market participants
Fig. 29 India oncology NGS market: Technology outlook and key takeaways
Fig. 30 India oncology NGS market: Technology movement analysis
Fig. 31 India oncology whole genome sequencing market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 32 India oncology whole exome sequencing market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 33 India oncology targeted & gene panel sequencing market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 34 India oncology NGS amplicon-based market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 35 India oncology NGS hybridization-based market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 36 India oncology NGS market: Application outlook and key takeaways
Fig. 37 India oncology NGS market: Application movement analysis
Fig. 38 India NGS-based oncology diagnostics and screening market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 39 India NGS-based oncology screening market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 40 India NGS-based sporadic cancer screening market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 41 India NGS-based inherited cancer screening market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 42 India NGS-based oncology CDx market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 43 India NGS-based other oncology diagnostics market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 44 India NGS-based oncology research studies market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 45 India oncology next-generation sequencing market: Product & service outlook and key takeaways
Fig. 46 India oncology next-generation sequencing market: Product & service movement analysis
Fig. 47 India oncology NGS platforms and related products market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 48 India oncology NGS panel market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 49 NGS consumables market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 50 India oncology NGS platforms market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 51 India oncology NGS services market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 52 India oncology NGS market: Workflow outlook and key takeaways
Fig. 53 India oncology NGS market: Workflow movement analysis
Fig. 54 India oncology NGS pre-sequencing market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 55 India oncology NGS library preparation kits market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 56 India oncology semi-automated library preparation market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 57 India oncology automated library preparation market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 58 India oncology clonal amplification market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 59 India oncology NGS sequencing market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 60 India oncology NGS data analysis market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 61 India oncology NGS primary data analysis market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 62 India oncology NGS secondary data analysis market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 63 India oncology NGS tertiary data analysis market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 64 India oncology next-generation sequencing market: End-use outlook and key takeaways
Fig. 65 India oncology next-generation sequencing market: End-use movement analysis
Fig. 66 Academic research-based India oncology NGS market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 67 Clinical research-based India oncology NGS market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 68 Hospitals & clinics -based India oncology NGS market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 69 Pharma & biotech entities -based India oncology NGS market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 70 Other users-based India oncology NGS market estimates and forecast, 2017 - 2028 (USD Million)
Note: Product cover images may vary from those shown
  • ILLUMINA, INC.
  • GENOTYPIC TECHNOLOGY PVT. LTD.
  • TECAN TRADING AG
  • SCIGENOM LABS PVT. LTD
  • XCELRIS LABS LTD. (XCELRIS GENOMICS)
  • EUROFINS SCIENTIFIC
  • 4BASECARE
  • MEDGENOME
  • SAYRE THERAPEUTICS
  • REDCLIFFE LIFE SCIENCES PVT. LTD.
  • PARTEK INCORPORATED
  • BIO-RAD LABORATORIES, INC.
  • MYRIAD GENETICS, INC.
  • HOLOGIC, INC. (GEN-PROBE INCORPORATED)
  • PERKIN ELMER, INC.
  • VELA DIAGNOSTICS
  • PREMAS LIFE SCIENCES
Note: Product cover images may vary from those shown

Loading
LOADING...